Venture Certified
| 연구개발유형 | 2015-05-13 ~ 2017-05-12 | 20150104275 | 2015-05-13 |
| 연구개발유형 | 2017-05-13 ~ 2019-05-12 | 20170105422 | 2015-05-13 |
| 연구개발유형 | 2019-05-13 ~ 2021-05-12 | 20190106603 | 2015-05-13 |
| 혁신성장유형 | 2021-05-13 ~ 2024-05-12 | 20210527030099 | 2015-05-13 |
| 혁신성장유형 | 2024-05-13 ~ 2027-05-12 | 20240611030026 | 2015-05-13 |
Revenue CAGR -20.8%
| Item | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 22.8B | 28.7B | 36.4B |
| Operating Profit | 7.0B | 14.0B | 17.3B |
| Net Profit | 10.3B | 14.3B | 16.9B |
| Total Assets | 76.4B | 74.2B | 58.4B |
| Total Liabilities | 0.7B | 7.5B | 5.1B |
| Total Equity | 75.7B | 66.7B | 53.3B |
▼ 29.9%
▼ 55.3%
▼ 36.4%
▼ 91.5%
▼ 48.7%
| Name | Position | Role |
|---|---|---|
| 김인섭 | 대표이사 | 대표 |
No Data – Contact
No procurement record or data not yet available| Tax Type | 부가가치세 일반과세자 |
| Status | Cert. flags confirmed (details update after further collection) |
1 Additional Data Sources
{
"address": "대전광역시 유성구",
"ceo_name": "김인섭",
"certificate": [
{
"cert_number": "20150104275",
"changes": "",
"disclosure_date": "2015-05-13",
"first_cert_date": "2015-05-13",
"no": "1",
"type": "연구개발유형",
"valid_period": "2015-05-13 ~ 2017-05-12"
},
{
"cert_number": "20170105422",
"changes": "",
"disclosure_date": "2017-05-24",
"first_cert_date": "2015-05-13",
"no": "2",
"type": "연구개발유형",
"valid_period": "2017-05-13 ~ 2019-05-12"
},
{
"cert_number": "20190106603",
"changes": "",
"disclosure_date": "2019-06-14",
"first_cert_date": "2015-05-13",
"no": "3",
"type": "연구개발유형",
"valid_period": "2019-05-13 ~ 2021-05-12"
},
{
"cert_number": "20210527030099",
"changes": "",
"disclosure_date": "2021-05-27",
"first_cert_date": "2015-05-13",
"no": "4",
"type": "혁신성장유형",
"valid_period": "2021-05-13 ~ 2024-05-12"
},
{
"cert_number": "20240611030026",
"changes": "",
"disclosure_date": "2024-06-11",
"first_cert_date": "2015-05-13",
"no": "5",
"type": "혁신성장유형",
"valid_period": "2024-05-13 ~ 2027-05-12"
}
],
"company_name": "(주) 바이오피에스",
"corp_no": "160111-*******",
"financials": {
"2022": {
"capital_stock": 245187000,
"cost_of_sales": 586720000,
"current_assets": 2089273000,
"current_liabilities": 112574000,
"gross_profit": 3049756000,
"net_income": 1685627000,
"net_income_bs": 1647971000,
"non_current_assets": 3749077000,
"non_current_liabilities": 400000000,
"non_operating_expenses": 77187000,
"non_operating_income": 34116000,
"operating_profit": 1728698000,
"revenue": 3636476000,
"sga_expenses": 1321058000,
"total_assets": 5838350000,
"total_equity": 5325776000,
"total_liabilities": 512574000
},
"2023": {
"capital_stock": 245187000,
"cost_of_sales": 546267000,
"current_assets": 3500858000,
"current_liabilities": 342625000,
"gross_profit": 2321835000,
"net_income": 1430947000,
"net_income_bs": 1345065000,
"non_current_assets": 3917608000,
"non_current_liabilities": 405000000,
"non_operating_expenses": 99908000,
"non_operating_income": 126128000,
"operating_profit": 1404727000,
"revenue": 2868102000,
"sga_expenses": 917108000,
"total_assets": 7418466000,
"total_equity": 6670841000,
"total_liabilities": 747625000
},
"2024": {
"capital_stock": 245187000,
"cost_of_sales": 590561000,
"current_assets": 5823407000,
"current_liabilities": 61786000,
"gross_profit": 1689069000,
"net_income": 1031454000,
"net_income_bs": 901061000,
"non_current_assets": 1815280000,
"non_current_liabilities": 5000000,
"non_operating_expenses": 74832000,
"non_operating_income": 406447000,
"operating_profit": 699839000,
"revenue": 2279630000,
"sga_expenses": 989230000,
"total_assets": 7638687000,
"total_equity": 7571901000,
"total_liabilities": 66786000
}
},
"industry": "의학 및 약학 연구개발업",
"investment": [],
"main_products": "비임상 안전성 검증시험",
"phone": "042-629-****",
"years": [
2024,
2023,
2022
]
}